Cable Hill Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Cable Hill Partners’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-500	Closed	-$6K	–	819
2018 Q2	$6K	Buy	+500	New	+$7.31K	﹤0.01%	603

Other funds holding IOVA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Cable Hill Partners's IOVA Position: Q3 2018 in Review

Cable Hill Partners sold out of Iovance Biotherapeutics (IOVA) in Q3 2018, closing a stake of 500 shares — an estimated $6K sold.

Cable Hill Partners first reported a position in IOVA in Q2 2018 and held it in 1 quarter. The position peaked at $6K in Q2 2018. 131 funds tracked by Wall St. Rank hold IOVA as of Q3 2018.

Cable Hill Partners reported no remaining Iovance Biotherapeutics position as of Q3 2018 after selling out during the quarter.
Cable Hill Partners sold 500 Iovance Biotherapeutics shares in Q3 2018, an estimated $6K.
Cable Hill Partners first reported a position in Iovance Biotherapeutics in Q2 2018 and held it in 1 quarter.
Cable Hill Partners's Iovance Biotherapeutics position peaked at $6K in Q2 2018.
131 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2018.

Based on Cable Hill Partners's 13F filing for Q3 2018, filed 14 Nov 2018.